Online inquiry

IVTScrip™ mRNA-Anti-IL13&IL4, SAR156597(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ14546MR)

This product GTTS-WQ14546MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets IL13&IL4 gene. The antibody can be applied in Idiopathic pulmonary fibrosis research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Chimeric; Humanized
RefSeq NM_001354991.2; NM_000589.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3596; 3565
UniProt ID P35225; P05112
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL13&IL4, SAR156597(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ14546MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4808MR IVTScrip™ mRNA-Anti-DPP4, BT 5/9(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BT 5/9
GTTS-WQ2542MR IVTScrip™ mRNA-Anti-GCGR, AMG 477(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AMG 477
GTTS-WQ8049MR IVTScrip™ mRNA-Anti-F, H1H3592P3(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA H1H3592P3
GTTS-WQ2879MR IVTScrip™ mRNA-Anti-CCR4, AMG-761(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA AMG-761
GTTS-WQ10802MR IVTScrip™ mRNA-Anti-G, M777-16-3(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA M777-16-3
GTTS-WQ4139MR IVTScrip™ mRNA-Anti-PDCD1, BI-754091(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BI-754091
GTTS-WQ10049MR IVTScrip™ mRNA-Anti-FN1, L19-IL-2(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA L19-IL-2
GTTS-WQ8736MR IVTScrip™ mRNA-Anti-CCR5, HuPRO-140(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA HuPRO-140
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW